<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00997269</url>
  </required_header>
  <id_info>
    <org_study_id>2008-0436</org_study_id>
    <secondary_id>AT004204</secondary_id>
    <nct_id>NCT00997269</nct_id>
  </id_info>
  <brief_title>Benefit of CoQ-10 in Patients on Statins</brief_title>
  <acronym>CoQ-10</acronym>
  <official_title>Benefit of CoQ-10 in Patients on Statins</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stony Brook University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stony Brook University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate whether a supplement called co-enzyme Q10 can help ease or&#xD;
      eliminate some of the side effects that result from taking statin medications. These side&#xD;
      effects include muscle pain, fatigue or muscle cramping.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Aim 1: to demonstrate that supplementation with coQ10 in patients treated with&#xD;
      statins ameliorates symptoms of muscle pain and fatigue and improves energy metabolism and&#xD;
      muscle function.&#xD;
&#xD;
      This objective will be achieved in a randomized, placebo-controlled double blind trial by&#xD;
      assessing the degree of muscle symptoms and interference of pain with daily activities,&#xD;
      aerobic capacity, and muscle function before and after supplementation with either coQ10 or&#xD;
      placebo in groups of statin-treated subjects.&#xD;
&#xD;
      Specific Aim 2: to examine changes at a molecular/cellular level that are associated with&#xD;
      improved pain and muscle function in statin-treated subjects supplemented with coQ10.&#xD;
&#xD;
      This aim will be addressed by analyzing muscle biopsies taken from statin-treated patients&#xD;
      before and after supplementation with coQ10 or placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain scores should be reduced</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Pain</condition>
  <condition>Soreness</condition>
  <condition>Weakness</condition>
  <condition>Fatigue</condition>
  <arm_group>
    <arm_group_label>CoQ-10 supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CoQ-10 placebo supplementation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Co-enzyme Q-10</intervention_name>
    <description>Patients will be supplemented with 300 mg of CoQ-10 1 time daily for one month</description>
    <arm_group_label>CoQ-10 supplementation</arm_group_label>
    <other_name>ubiquinone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will be supplemented with CoQ-10 placebo 1 time daily for one month</description>
    <arm_group_label>CoQ-10 placebo supplementation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult men and women 21 years and older taking statin medications for hyperlipidemia&#xD;
             under the current National Cholesterol Education Program guidelines (NCEP III) and&#xD;
             complaining of myopathic symptoms.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. diagnosis of cancer;&#xD;
&#xD;
          2. acute illness of any sort;&#xD;
&#xD;
          3. hemoglobin less than 12,&#xD;
&#xD;
          4. creatinine greater than 1.5 mg/dl;&#xD;
&#xD;
          5. liver dysfunction as evidenced by elevations in transaminases 3-fold higher than upper&#xD;
             limit of normal;&#xD;
&#xD;
          6. use of certain medications or nutritional supplements within the past month;&#xD;
&#xD;
          7. untreated hypertension (diastolic BP&gt; 100 mm HG);&#xD;
&#xD;
          8. diagnosis of diabetes mellitus (fasting blood glucose &gt; 126 mg/dl);&#xD;
&#xD;
          9. untreated hypothyroidism;&#xD;
&#xD;
         10. overt congestive heart failure (by physical exam);&#xD;
&#xD;
         11. active inflammatory diseases such as rheumatoid arthritis, lupus, etc.,&#xD;
&#xD;
         12. bleeding disorders;&#xD;
&#xD;
         13. history of adverse reactions besides myopathy associated with the use of statins;&#xD;
&#xD;
         14. any previous adverse reaction to coQ10 or to multivitamin supplements containing&#xD;
             coQ10;&#xD;
&#xD;
         15. plasma CPK levels &gt; 3 times the upper normal limit; OR&#xD;
&#xD;
         16. congenital myopathies and/or neuromuscular degenerative diseases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Caso, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stony Brook University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stony Brook University GCRC</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>October 16, 2009</study_first_submitted>
  <study_first_submitted_qc>October 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2009</study_first_posted>
  <last_update_submitted>April 28, 2016</last_update_submitted>
  <last_update_submitted_qc>April 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CoQ-10</keyword>
  <keyword>statin</keyword>
  <keyword>muscle pain</keyword>
  <keyword>cardiovascular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ubiquinone</mesh_term>
    <mesh_term>Coenzyme Q10</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

